Morales, María Luz http://orcid.org/0000-0002-0685-8441
García-Vicente, Roberto http://orcid.org/0000-0002-4796-9391
Rodríguez-García, Alba http://orcid.org/0000-0002-6786-2006
Reyes-Palomares, Armando http://orcid.org/0000-0002-0289-6889
Vincelle-Nieto, África http://orcid.org/0000-0002-0112-9047
Álvarez, Noemí
Ortiz-Ruiz, Alejandra http://orcid.org/0000-0003-4059-8839
Garrido-García, Vanesa
Giménez, Alicia
Carreño-Tarragona, Gonzalo http://orcid.org/0000-0002-9570-5542
Sánchez, Ricardo http://orcid.org/0000-0002-6383-0381
Ayala, Rosa
Martínez-López, Joaquín http://orcid.org/0000-0001-7908-0063
Linares, María http://orcid.org/0000-0003-3180-6560
Funding for this research was provided by:
Fundación Española de Hematología y Hemoterapia
Regional Programme of Research and Technological Innovation for Young Doctors UCM-CAM
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI16/01530, PI19/01518)
Asociacion Española contra el Cáncer
Article History
Received: 7 February 2023
Revised: 14 June 2023
Accepted: 29 June 2023
First Online: 8 July 2023
Competing interests
: RS: Altum sequencing: Employment. RA: Novartis and Incyte: Advisory Board; Astellas, Celgene and Novartis: Speaker honorarium; Altum sequencing: Board of directors. JML: BMS, Novartis, Janssen and Astellas: Grants; BMS, Novartis, Janssen, Incyte, Astellas, Takeda and Kite: Speaking Bureau; Vivia Biotech and Altum Sequencing: Board of directors. The remaining authors declare no competing financial interests.